Evercore ISI initiated coverage on shares of Henry Schein (NASDAQ:HSIC) in a research report sent to investors on Thursday, January 4th, Marketbeat.com reports. The brokerage issued an outperform rating and a $81.00 price target on the stock.
A number of other research firms also recently weighed in on HSIC. Robert W. Baird set a $95.00 price target on shares of Henry Schein and gave the company a buy rating in a report on Thursday, October 19th. Stifel Nicolaus dropped their target price on shares of Henry Schein from $89.00 to $77.00 and set a hold rating on the stock in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Henry Schein from a hold rating to a sell rating in a report on Monday, November 13th. Craig Hallum upgraded shares of Henry Schein from a hold rating to a buy rating in a report on Tuesday, November 7th. Finally, UBS Group reiterated a buy rating on shares of Henry Schein in a report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $84.23.
Shares of Henry Schein (NASDAQ HSIC) traded down $0.66 during trading hours on Thursday, hitting $72.79. 1,624,600 shares of the company’s stock were exchanged, compared to its average volume of 1,338,186. The firm has a market cap of $11,500.00, a price-to-earnings ratio of 20.98, a P/E/G ratio of 1.89 and a beta of 0.99. Henry Schein has a 52 week low of $65.28 and a 52 week high of $93.50. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30.
Henry Schein announced that its board has initiated a stock repurchase program on Monday, September 18th that authorizes the company to repurchase $400.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
In other news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.19% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. YorkBridge Wealth Partners LLC boosted its position in shares of Henry Schein by 5.2% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock valued at $104,000 after acquiring an additional 28 shares in the last quarter. Sun Life Financial INC boosted its position in shares of Henry Schein by 8,185.7% during the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock valued at $106,000 after acquiring an additional 573 shares in the last quarter. FTB Advisors Inc. boosted its position in shares of Henry Schein by 100.0% during the 3rd quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock valued at $120,000 after acquiring an additional 742 shares in the last quarter. Trust Co. of Vermont boosted its position in shares of Henry Schein by 56.7% during the 3rd quarter. Trust Co. of Vermont now owns 1,702 shares of the company’s stock valued at $140,000 after acquiring an additional 616 shares in the last quarter. Finally, Lee Financial Co boosted its position in shares of Henry Schein by 100.0% during the 3rd quarter. Lee Financial Co now owns 1,756 shares of the company’s stock valued at $144,000 after acquiring an additional 878 shares in the last quarter. Institutional investors and hedge funds own 91.69% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.